Cubist Pharmaceuticals has acquired 5 companies of its own.
Cubist Pharmaceuticals’ largest acquisition to date was in 2013, when it acquired Optimer Pharmaceuticals for $801M. Cubist Pharmaceuticals has acquired in 4 different US states. The Company’s most targeted sectors include life science (100%).
65 Hayden Avenue,
Lexington, Massachusetts
02421
United States,
(781) 860-8660
www.cubist.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2013-10-24 |
Optimer Pharmaceuticals, Inc. · Life Science
Jersey City, New Jersey · www.optimerpharma.com Optimer Pharmaceuticals, Inc., a biopharmaceutical company currently focused on commercializing our antibiotic product DIFICID® (fidaxomicin) tablets in the United States and Canada, and developing other fidaxomicin products in the United States and worldwide, both independently and in our conjunction with partners and licensees. Advisors: Centerview Partners , J.P. Morgan Securities , Sullivan & Cromwell |
801 | Add-on Acquisition |
Cubist Pharmaceuticals, Inc.
|
- | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
